# Axial Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axial-biotech

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: www.axialbiotech.com
- Total disclosed funding: $14M
- Latest round: Series B (Mar 27, 2007)
- Investors on record: 4

## About

Axial Biotech is focused on digital real estate in the biotechnology sector, offering premium domain names, particularly AxialBiotech.com, to enhance online visibility for biotech companies and institutions.Founded in 2002 in Salt Lake City, US, Axial Biotech specializes in providing premium domain names for the biotech sector. The company was involved in a significant transaction on August 28, 2012, when Transgenomic acquired its ScoliScore Adolescent Idiopathic Scoliosis Prognostic Test Business for USD 4.4 million in cash. The founder's previous entrepreneurial history is not publicly documented, and there are no known pivots in business strategy or subsidiaries associated with the company.AxialBiotech.com specializes in the sale of premium domain names, particularly the flagship domain AxialBiotech.com, which caters to businesses in the biotechnology sector. This domain serves as a valuable digital asset for companies looking to establish a strong online presence. Primary end users include biotech startups, research institutions, and established pharmaceutical companies focused on increasing their visibility and accessibility in the market. The company markets its offerings primarily in North America and Europe, targeting regions with significant investment in biotech, such as the United States, Germany, and the United Kingdom.AxialBiotech.com generates revenue through domain sales, with the flagship domain priced at USD 3,995. Purchases can be made outright or with a payment plan of USD 166.46 per month for 24 months, facilitating access for a diverse clientele, from startups to established firms. The company employs a direct-to-consumer sales approach, ensuring prompt access to the purchased domain, typically within one to two hours after the transaction.The company aims to expand its service offerings and enhance its market presence. While specific new products have not been detailed, the company plans to leverage its recent funding, which was part of a Trade Sale that raised USD 4.4 million, to support these initiatives. There are no specific new geographic markets identified for expansion as of now, but the company continues to focus on North America and Europe as principal regions for growth.

## Funding rounds

- Series B, Mar 27, 2007, $9.5M — Signal Peak Ventures, Johnson & Johnson Innovation
- Series A, Mar 1, 2005, $4.1M — Signal Peak Ventures, Certain tonometry assets of Medtronic Inc., Medtronic Ventures

## Investors

- Signal Peak Ventures (https://capitalatlas.ai/funds/signal-peak-ventures) — Series A, Series B
- Certain tonometry assets of Medtronic Inc. — Series A
- Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B